ERGO (Epidemic diseases Research Group Oxford)
The overarching aim of the Epidemic diseases Research Group Oxford (ERGO) is to reduce the health and socioeconomic impact of emerging and epidemic infections by conducting and enabling clinical research on emerging and epidemic infections.Learn more
PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics)
PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics) is an EU funded network for harmonised large-scale clinical research studies on infectious diseases.Learn more
ALERRT (The African coaLition for Epidemic Research, Response and Training)
The African coaLition for Epidemic Research, Response and Training (ALERRT) is a multi-disciplinary consortium building a patient-centered clinical research network to respond to epidemics across sub-Saharan AfricaLearn more
UK-PHRST (UK Public Health Rapid Support Team)
The UK-PHRST, funded by UK aid from the Department of Health and Social Care, supports low- and middle-income countries in investigating and responding to disease outbreaks and conducts research to improve our response to future epidemics.Learn more
ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium)
ISARIC is a global federation of clinical research networks, providing a proficient, coordinated, and agile research response to outbreak-prone infectious diseases.Learn more
RECOVERY: Randomised Evaluation of COVID-19 Therapy
Led by ERGO's Peter Horby, this national clinical trial aims to identify treatments that may be beneficial for adults hospitalised with confirmed COVID-19. The trial is being conducted in over 130 NHS hospitals across the UK. Adult patients who have been admitted to hospital with COVID-19 are being invited to take part, and more information can be found at https://www.recoverytrial.net/.
Watch Peter discussing the trial on our Talks and Videos page.
Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within ...
To make clinical and biological observations within a timeframe that is likely to benefit patients during disease outbreaks, coordination of global research must match the speed of spread of novel ...
Conclusions: Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public ...
The largest prospective observational study to date provides a comprehensive picture of the patients’ outcomes and characteristics that have been hospitalised in the UK with covid-19. Age, gender, obesity and ...
The Lancet - 29th April 2020 No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, ...
Professor Peter Horby and Professor Martin Landray, chief investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, said: In March this year, RECOVERY was established as a randomised clinical trial to test a range of potential treatments for COVID-19, ... Read more